2024 年第 4 期 第 0 卷

格隆溴铵福莫特罗联合呼吸训练对慢性阻塞性肺疾病稳定期患者呼吸功能及炎症因子水平的影响研究

Study on the effect of glycopyrronium bromide and formoterol combined with respiratory training on respiratory function and inflammatory factor levels in stable chronic obstructive pulmonary disease patients

作者：王蕾陈忠仁梁海梅冯书王少娜杨绪莉王小强黄丝妮王捷平

英文作者：Wang Lei Chen Zhongren Liang Haimei Feng Shu Wang Shaona Yang Xuli Wang Xiaoqiang Huang Sini Wang Jieping

单位：海南省海口市人民医院呼吸与危重症医学科，海口570208

英文单位：Department of Respiratory and Critical Care Medicine Haikou People′s Hospital Hainan Province Haikou 570208 China

关键词：慢性阻塞性肺疾病；福莫特罗；格隆溴铵；呼吸训练；呼吸功能

英文关键词：Chronicobstructivepulmonarydisease;Formoterol;Glycopyrroniumbromide;Respiratorytraining;Respiratoryfunction

• 摘要：

• 目的 研究格隆溴铵福莫特罗联合呼吸训练对慢性阻塞性肺疾病（COPD）稳定期患者呼吸功能及白细胞介素8（IL-8）、磷酸二酯酶4（PDE4）的影响。方法 选取海南省海口市人民医院2021年2月至2023年2月收治的COPD稳定期患者100例，依据随机数字表法分为对照组、观察组，各50例。对照组应用格隆溴铵福莫特罗吸入气雾剂治疗，观察组在对照组基础上联合呼吸训练治疗。2组均治疗3个月。比较2组治疗前后呼气峰流速（PEF）、第1秒用力呼气容积（FEV1）及FEV1占预计值百分比（FEV1%）、COPD疾病评估测试（CAT）评分、生活质量评分（SGRQ）、动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）以及IL-8、PDE4水平。结果 治疗后，2组PEF、FEV1及FEV1%均高于治疗前，且观察组均高于对照组［（2.7±0.5）L/s比（2.1±0.5）L/s、（2.4±0.6）L比（1.9±0.5）L、（70.1±2.6）%比（60.4±1.3）%］（均P＜0.05）；2组CAT、SGRQ、PaCO2均低于治疗前、且观察组均低于对照组，2组PaO2均高于治疗前、且观察组高于对照组（均P＜0.05）；2组IL-8、PDE4水平均低于治疗前，且观察组均低于对照组（均P<0.05）。结论 格隆溴铵福莫特罗联合呼吸训练有利于增强COPD稳定期患者呼吸功能，改善血氧供给及COPD病情，优化生活质量，抑制炎症因子水平。

• Objective To study the effects of glycopyrronium bromide and formoterol combined with respiratory training on respiratory function and impacts on interleukin-8 (IL-8) and phosphodiesterase 4 (PDE4) in patients with stable chronic obstructive pulmonary disease (COPD). Methods A total of 100 patients with stable COPD admitted to Haikou People′s Hospital, Hainan Province from February 2021 to February 2023 were selected. Patients were divided into control group and observation group according to the random number table method, with 50 cases each. The control group was treated with glycopyrronium bromide and formoterol, and the observation group was treated with respiratory training based on the control group. Both groups were treated for 3 months. Peak flow rate (PEF), forced expiratory volume in the first second (FEV1), FEV1 as a percentage of expected value (FEV1%), COPD assessment test (CAT) score, quality of life score (SGRQ), arterial partial pressure of oxygen (PaO2), arterial blood carbon dioxide partial pressure (PaCO2) and IL-8 and PDE4 levels were compared between the two groups before and after treatment. Results After treatment, PEF, FEV1 and FEV1% in both groups were higher than those before treatment and the levels in the observation group were higher than those in the control group ［（2.7±0.5）L/s vs （2.1±0.5）L/s,（2.4±0.6）L vs （1.9±0.5）L,（70.1±2.6）% vs （60.4±1.3）%］(all P<0.05). CAT, SGRQ and PaCO2 in both groups after treatment were lower than those before treatment and the levels in the observation group were lower than those in the control group; PaO2 in both groups after treatment were higher than those before treatment and the level in the observation group was higher than that in the control group(all P<0.05). Levels of IL-8 and PDE4 in both groups after treatment were lower than those before treatment and the levels in the observation group were lower than those in the control group (all P<0.05). Conclusions Combined respiratory training with glycopyrronium bromide and formoterol is beneficial for enhancing respiratory function, improving blood oxygen supply and COPD condition, optimizing quality of life, and suppressing inflammatory factor levels in patients with stable COPD.